Effect of thiamine administration on metabolic profile, cytokines and inflammatory markers in drug-na⟨ve patients with type 2 diabetes

To evaluate the effect of thiamine administration on metabolic profile, cytokines and inflammatory markers in drug-na < ve patients with type 2 diabetes mellitus (T2DM). A randomized, double-blind, placebo-controlled, pilot-scale clinical trial was carried out in 24 patients with T2DM. Twelve subjects received thiamine orally (150 mg), once daily during a fasting state for 1 month. An additional 12 patients (control group) were given placebo for the same period of time. Before and after the intervention, fasting glucose, A1C, creatinine, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, very low-density lipoprotein, high-sensitive C-reactive protein, interleukin 6, tumor necrosis factor-alpha, leptin and adiponectin levels were estimated. Wilcoxon's signed-rank and Mann-Whitney U test were used for statistical analyses. There were significant decreases in glucose (6.7 +/- A 1.0 mmol/l vs. 6.0 +/- A 1.0 mmol/l, p = 0.024) before and after the intervention, respectively, and leptin concentrations (32.9 +/- A 13.3 ng/ml vs. 26.9 +/- A 12.8 ng/ml, p = 0.027) before and after the intervention, respectively, with thiamine administration. There were no changes with the rest of the measurements. Thiamine administration for 1 month decreased glucose and leptin concentrations in drug-na < ve patients with T2DM.